|1.||Takaoka, Munenori: 7 articles (01/2015 - 07/2008)|
|2.||Hatakeyama, Shinji: 7 articles (01/2015 - 04/2007)|
|3.||Naomoto, Yoshio: 7 articles (01/2015 - 07/2008)|
|4.||Fukazawa, Takuya: 4 articles (11/2012 - 12/2008)|
|5.||Yamatsuji, Tomoki: 4 articles (07/2012 - 07/2008)|
|6.||Sakurama, Kazufumi: 4 articles (07/2012 - 07/2008)|
|7.||Ohmori, Osamu: 4 articles (01/2009 - 04/2007)|
|8.||Tomono, Yasuko: 3 articles (07/2012 - 07/2008)|
|9.||Watanabe, Nobuyuki: 3 articles (01/2009 - 07/2008)|
|10.||Motoki, Takayuki: 3 articles (01/2009 - 07/2008)|
|1.||Breast Neoplasms (Breast Cancer)
03/01/2008 - "In the present study, we studied the effect of a novel FAK inhibitor, TAE226 (Novartis, Inc.), on the breast cancer cell lines. "
03/01/2008 - "We used stable breast cancer cell lines overexpressing Src (MCF-7-Src and BT474-Src) or overexpressing EGFR (BT474-EGFR), and control breast cancer cell lines for the treatment with different doses of TAE226 drug. "
05/01/2011 - "Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo."
03/01/2008 - "Thus, inhibition of autophosphorylation activity of FAK with the TAE226 inhibitor at 10-20 microM is effective in causing apoptosis in breast cancer cells, resistant to the Ad-FAK-CD inhibitor that can be used effectively in therapy."
05/01/2011 - "Oral administration of TAE226 in mice significantly decreased bone metastasis and osteoclasts involved which were induced by MDA-MB-231 breast cancer cells and increased the survival rate of the mouse models of bone metastasis. "
06/01/2007 - "As all glioma cell lines examined expressed phosphorylated FAK, we examined the efficacy of a novel low-molecular weight inhibitor of FAK, TAE226, against human glioma cell lines. "
06/01/2007 - "Together, these data demonstrate the potential benefit of TAE226 for glioma therapy."
06/01/2007 - "TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. "
04/01/2007 - "Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas."
04/01/2007 - "More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model. "
|3.||Esophageal Neoplasms (Esophageal Cancer)
12/01/2008 - "We examined the expression of mTOR and S6 in esophageal cancer cells (SEG-1) and normal esophageal epithelial cells (KOB-13) and the efficacy of TAE226 against SEG-1 cells. "
12/01/2008 - "Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment."
12/01/2008 - "TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells."
07/15/2008 - "When esophageal adenocarcinoma cells were treated with TAE226, cell proliferation and migration were greatly inhibited with an apparent structural change of actin fiber and a loss of cell adhesion. "
07/15/2008 - "These results suggest that TAE226, a dual tyrosine kinase inhibitor for FAK and IGF-IR, could become a new remedy for Barrett's esophageal adenocarcinoma."
07/15/2008 - "Cultured esophageal adenocarcinoma cells were treated with TAE226, a specific FAK inhibitor with an additional effect of inhibiting insulin-like growth factor-I receptor (IGF-IR), to assess its anticancer effect in vitro. "
|1.||Focal Adhesion Protein-Tyrosine Kinases
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||Dihydrotachysterol (AT 10)
|7.||Small Interfering RNA (siRNA)
|8.||IGF Type 1 Receptor (IGF 1 Receptor)
|10.||Ribosomal Proteins (Ribosomal Protein)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)